Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis : role of macrophages and fibroblasts in the liver

1. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution

of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci. 1999;892:146–154. doi:

10.1111/j.1749-6632.1999.tb07793.x.

2. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or

cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi: 10.1038/nrgastro.2013.41.

3. Younossi ZM. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol.

2019;70(3):531–544. doi: 10.1016/j.jhep.2018.10.033.

4. Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver

Dis. 2012;16(3):631–645. doi: 10.1016/j.cld.2012.05.003.

5. Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific

region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73. doi: 10.1038/s41575-018-0055-0.

6. Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150(8):1769–

1777. doi: 10.1053/j.gastro.2016.02.066.

7. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi: 10.1002/hep.30251.

8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study

of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–1609.

396

Michiko Itoh et al

doi: 10.1053/j.gastro.2012.04.001.

9. Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol.

2016;13(4):196–205. doi: 10.1038/nrgastro.2016.3.

10. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients

with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi: 10.1016/j.

jhep.2019.06.021.

11. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality

in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554. doi: 10.1002/hep.27368.

12. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with

long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.

doi: 10.1053/j.gastro.2015.04.043.

13. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of causespecific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.

Gastroenterology. 2018;155(2):443–457. doi: 10.1053/j.gastro.2018.04.034.

14. Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the

clinic. Hepatol Int. 2020;14(1):8–23. doi: 10.1007/s12072-019-10001-4.

15. Liu Y, Meyer C, Xu C, et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver

Physiol. 2013;304(5):G449–468. doi: 10.1152/ajpgi.00199.2012.

16. Farrell G, Schattenberg JM, Leclercq I, et al. Mouse models of nonalcoholic steatohepatitis: toward

optimization of their relevance to human nonalcoholic steatohepatitis. Hepatology. 2019;69(5):2241–2257.

doi: 10.1002/hep.30333.

17. Ito M, Suzuki J, Tsujioka S, et al. Longitudinal analysis of murine steatohepatitis model induced by chronic

exposure to high-fat diet. Hepatol Res. 2007;37(1):50–57. doi: 10.1111/j.1872-034X.2007.00008.x.

18. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of hepatic fibrosis in a murine

model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol. 2008;173(4):993–1001. doi:

10.2353/ajpath.2008.070720.

19. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased

collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology. 2002;35(4):762–771.

doi: 10.1053/jhep.2002.32029.

20. Itoh M, Suganami T, Nakagawa N, et al. Melanocortin 4 receptor-deficient mice as a novel mouse model

of nonalcoholic steatohepatitis. Am J Pathol. 2011;179(5):2454–2463. doi: 10.1016/j.ajpath.2011.07.014.

21. Suganami T, Tanaka M, Ogawa Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocr J.

2012;59(10):849–857. doi: 10.1507/endocrj.ej12-0271.

22. Balthasar N, Dalgaard LT, Lee CE, et al. Divergence of melanocortin pathways in the control of food

intake and energy expenditure. Cell. 2005;123(3):493–505. doi: 10.1016/j.cell.2005.08.035.

23. Nogueiras R, Wiedmer P, Perez-Tilve D, et al. The central melanocortin system directly controls peripheral

lipid metabolism. J Clin Invest. 2007;117(11):3475–3488. doi: 10.1172/JCI31743.

24. Tanaka M, Suganami T, Sugita S, et al. Role of central leptin signaling in renal macrophage infiltration.

Endocr J. 2010;57(1):61–72. doi: 10.1507/endoerij.k09e-296.

25. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. doi:

10.1016/s0016-5085(98)70599-2.

26. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel

hits hypothesis. Hepatology. 2010;52(5):1836–1846. doi: 10.1002/hep.24001.

27. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent

features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125(2):437–443. doi: 10.1016/

s0016-5085(03)00907-7.

28. Goto T, Itoh M, Suganami T, et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in

a murine model of nonalcoholic steatohepatitis. Sci Rep. 2018;8(1):8157. doi: 10.1038/s41598-018-26383-8.

29. Komiya C, Tanaka M, Tsuchiya K, et al. Antifibrotic effect of pirfenidone in a mouse model of human

nonalcoholic steatohepatitis. Sci Rep. 2017;7:44754. doi: 10.1038/srep44754.

30. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model

of nonalcoholic steatohepatitis. Hepatology. 2009;50(5):1421–1430. doi: 10.1002/hep.23167.

31. Itoh M, Kato H, Suganami T, et al. Hepatic crown-like structure: a unique histological feature in

non-alcoholic steatohepatitis in mice and humans. PLoS One. 2013;8(12):e82163. doi: 10.1371/journal.

pone.0082163.

32. Itoh M, Suganami T, Kato H, et al. CD11c+ resident macrophages drive hepatocyte death-triggered liver

fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight. 2017;2(22):e92902. doi: 10.1172/

397

Role of chronic inflammation in NASH

jci.insight.92902.

33. Satoh T, Nakagawa K, Sugihara F, et al. Identification of an atypical monocyte and committed progenitor

involved in fibrosis. Nature. 2017;541(7635):96–101. doi: 10.1038/nature20611.

34. Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology.

2009;50(1):185–197. doi: 10.1002/hep.22952.

35. Miura, K., Yang, L., van Rooijen, N., Ohnishi, H. & Seki, E. Hepatic recruitment of macrophages promotes

nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302(11):G1310–

1321. doi:10.1152/ajpgi.00365.2011.

36. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol.

2017;14(7):397–411. doi: 10.1038/nrgastro.2017.38.

37. Burt AD. Pathobiology of hepatic stellate cells. J Gastroenterol. 1999;34(3):299–304. doi: 10.1007/

s005350050264

38. Asakawa M, Itoh M, Suganami T, et al. Upregulation of cancer-associated gene expression in activated

fibroblasts in a mouse model of non-alcoholic steatohepatitis. Sci Rep. 2019;9(1):19601. doi: 10.1038/

s41598-019-56039-0.

39. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi:

10.1038/nrc.2016.73.

...